NAD+ Injectable Drug Recalled for Microbial Contamination and Elevated Endotoxin Levels
GenoGenix LLC is recalling NAD+ for Injection due to microbial contamination and elevated endotoxin levels in lot GG121624-023. The Class I recall affects 100 mg/mL and 200 mg/mL products distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I is the most serious classification for drug recalls, mandating a minimum severity score of 4 per the rubric. Microbial contamination with elevated endotoxin levels in sterile injectable products represents a direct health hazard to patients.
Plain-English summary
GenoGenix LLC is recalling NAD+ (Nicotinamide adenine dinucleotide) for Injection in two concentrations: 100 mg/mL and 200 mg/mL supplied in 10 mL multi-dose amber vials. Lot number GG121624-023 has been distributed nationwide to healthcare facilities and pharmacies.
The product is being recalled because of microbial contamination and elevated endotoxin levels detected in the sterile product. Endotoxin contamination in injectable products poses a health hazard to patients receiving injections.
Healthcare providers are advised to discontinue use of this product lot immediately and quarantine any remaining inventory. Patients who may have received injections from lot GG121624-023 should contact their healthcare provider for guidance.
For more information about this Class I recall, contact the U.S. Food and Drug Administration or GenoGenix LLC, located in Boca Raton, Florida.
The recalled product
- Product
- NAD+ (Nicotinamide adenine dinucleotide) for Injection, a) 100 mg/mL b) 200 mg/mL, 10 mL multi-dose amber vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.
- Manufacturer
- GenoGenix LLC
- Hazard
- microbial-contamination
- endotoxin
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: GG121624-023
- within expiry
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27